FDA Real-Time Trial Data Pilot: What Sponsors Should Do
FDA's real-time clinical trial data pilot puts reviewers inside the data stream mid-trial. What it means for Phase 2-3 sponsors and AI monitoring.
FDAclinical trialsICH E6regulatory strategy
Blog
Regulatory compliance for biotech teams. No fluff, no "contact us to learn more."
Utah Clinical AI Sandbox: What Founders Still Owe the FDA
Utah's clinical AI sandbox gives diagnostic and treatment AI room to run, but HIPAA, the state medical board, malpractice and FDA pre-sub still apply.
clinical AISaMDFDAregulatory strategy
The $300/Hour Cross-Reference Problem
I priced six biotech consulting invoices line by line. About 60% of every bill is mechanical cross-referencing — work nobody should be paying $300 an hour for.
regulatory consultantsbiotech costsAI complianceconsultant invoices
I Read All 24 ICH Guidelines Over a Weekend. Here's What Surprised Me
Two days, 1,800+ pages of ICH guidelines, three contradictions, and one footnote that explains half the clinical holds I've seen. A close reading nobody actually does.
ICH guidelinesregulatorypreclinicalICH M3
One IND Per Workspace: Why We Made Isolation the Default
Most AI compliance tools treat your data like a shared bucket. We don't. Here's why workspace isolation is the only architecture that survives a pre-IND IP question.
AI securityworkspacesdata isolationpre-IND
5 Preclinical Gaps That Stop Phase 1 Trials Before They Start
Clinical hold post-mortem for Clinical Trial Management leads — five preclinical gaps that get IND submissions paused, with the ICH section behind each one.
Clinical Trial ManagementClinical HoldINDPreclinical
What Clinical Trial Management Software Actually Does in 2026
A plain-English guide to Clinical Trial Management Software (CTMS) — what it does, what it doesn't, and the regulatory gap most CTMS platforms leave open before site activation.
Clinical Trial ManagementCTMSINDCompliance
What Otarmeni Means for AAV Gene Therapy Preclinical Packages
Regeneron's Otarmeni is the first FDA-approved gene therapy for inherited hearing loss. Here's what its approval signals to biotech teams building AAV preclinical packages today.
Gene TherapyAAVPreclinicalFDA Approval
Can You Trust AI in Regulatory Work? An Honest Answer
When biotech RA leads ask whether AI can be trusted with FDA submissions, the question is usually wrong. Here's what trust means in regulatory work and how to evaluate AI vendors against it.
AIregulatory affairs21 CFR Part 11FDA
You've Outgrown REDCap. Here's How to Tell.
Eight signs your team has hit the ceiling on REDCap — multicenter pain, version hell, CSV form-building, and what to look at when it's time to move on.
REDCapresearch workspaceclinical datadata capture
From REDCap Data to IND Submission Without the Copy-Paste Marathon
How clinical research data flows into CTD Module 2 and Module 5 — what's actually manual today, what ICH M4 requires, and how an orchestration layer cuts the bridge from weeks to days.
IND submissionCTDREDCapregulatory affairs
Will Your AI Compliance Vendor Train on Your IND? 7 Questions to Ask
Your AI compliance vendor is either retaining your IND data, training on it, or both. Unless you asked these 7 questions. A due diligence checklist for pharma and finance buyers.
securityAI complianceSOC 2HIPAA
The 5 Part 38 Core Principles That Kill DCM Applications
Most CFTC DCM applications stall on the same 5 Core Principles. Exact CFR sections, why staff push back, what a materially complete exhibit actually looks like. With 17 CFR Part 38 citations.
CFTCDCMPart 38Core Principles
7 Tools CFTC DCM Applicants Actually Need (2026 Comparison)
We tested every RegTech tool relevant to DCM designation. Eventus, Ascent, Harvey, NICE Actimize, SteelEye, CUBE, Behavox. Here's what works, what doesn't, and what's still missing.
CFTCDCMcomplianceRegTech
GLP Training Requirements: What FDA Actually Expects from Lab Personnel
Training failures account for 81% of GLP 483 observations in a single year. Here's what 21 CFR 58.29 requires, what inspectors check, and how to build training records that survive an audit.
GLPTrainingFDACompliance
GLP vs Non-GLP Studies: When Each Applies for Your IND
Which preclinical studies require GLP compliance and which don't? Practical decision framework based on 21 CFR Part 58 scope, ICH M3(R2), and real sponsor mistakes.
GLPpreclinicalINDcompliance
GLP Data Integrity: ALCOA+ Checklist for Electronic Lab Systems
ALCOA+ principles mapped to GLP lab practice — audit trails, electronic records, Part 11 compliance, and what FDA warning letters reveal about data integrity failures in nonclinical studies.
GLPData IntegrityALCOACompliance
Regfo vs Weave Bio: Which One You Actually Need
Weave Bio builds eCTD submission documents. Regfo checks your protocol against FDA/ICH rules before you submit. Different tools, different problems — here's how to pick.
Competitor ComparisonFDA ComplianceIND Submission
FDA GLP Inspections: What 483 Data Reveals About Preclinical Compliance
FDA's own GLP 483 trend data (FY2020–FY2024) shows training and SOP failures dominate observations — but warning letters follow data integrity and Study Director breakdowns. Here's what that split means.
GLPFDACompliancePreclinical
The Most Common Preclinical Compliance Gaps (FDA Data)
We pulled FDA's published data on IND clinical holds and GLP warning letters. The biggest preclinical compliance gaps aren't where most teams look.
ComplianceINDFDAPreclinical
ICH S6(R1) Nonclinical Safety for mAbs: What Actually Changes
ICH S6(R1) requirements for monoclonal antibody nonclinical programs: species selection, NHP defaults, dosing, immunogenicity, and FDA's 2024 draft.
ICH GuidelinesNonclinicalBiologics
SEND Data Standards for Nonclinical IND Submissions
What SEND is, which nonclinical studies need it, how to build the datasets, and the errors FDA flags most often. A practical guide for IND-stage biotechs.
SENDNonclinicalIND
12 Best FDA Compliance Software for Biotech in 2026
We compared 12 FDA compliance tools — from $100K enterprise QMS to $399/mo AI gap analysis. Real G2 reviews, honest pros/cons, pricing for each.
comparisonFDA complianceQMSbiotech
FDA Expedited Programs: Fast Track, Breakthrough, Accelerated Approval
Clear comparison of FDA's 4 expedited programs — Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. Eligibility criteria, how to apply, nonclinical implications, and real timelines.
FDAFast TrackBreakthrough TherapyAccelerated Approval
Clinical Holds: Why FDA Stops Trials and How to Prevent It
Complete guide to FDA clinical holds — the 7 most common reasons, how 21 CFR 312.42 works, real examples, and what to do if you get one. Prevention strategies for biotech sponsors.
clinical holdFDAINDpreclinical
IND-Enabling Studies: Timeline, Cost, and What You Need
Complete guide to IND-enabling nonclinical studies — what's required, realistic timelines, costs by study type, CRO selection, and how to build a Phase 1-enabling package without wasting 6 months.
IND-enablingpreclinicaltoxicologytimeline
How to Write CTD Module 2.4 Nonclinical Overview
Practical guide to writing the CTD Module 2.4 Nonclinical Overview for IND submissions. Structure, content, dose justification, what FDA reviewers look for, and common mistakes.
CTDModule 2.4Nonclinical OverviewIND
ICH M4Q(R2): Your CTD Quality Section Is About to Change
First major CTD quality revision in 23 years. New Module 2.3 structure, DMCS template, Core Quality Information concept. What changes, when, and what to do now.
ICH M4QCTDModule 3CMC
Pre-IND Meeting with FDA: How to Prepare and What to Expect
Step-by-step guide to requesting and preparing for a Type B pre-IND meeting with FDA. Briefing document format, timeline, common mistakes, and what FDA actually responds to. Based on 21 CFR 312.82.
FDApre-INDINDregulatory strategy
ICH S7A Safety Pharmacology: Core Battery Requirements
Complete guide to ICH S7A core battery — cardiovascular (hERG, telemetry), respiratory, and CNS assessments. GLP requirements, study timing, common deficiencies, and how S7B integrates for QT risk.
ICH S7Asafety pharmacologyhERGcore battery
Species Selection for Toxicology Studies: ICH S6 and S9 Guide
How to choose the right animal species for nonclinical toxicology studies. ICH S6(R1) for biologics, ICH S9 for oncology, and ICH M3(R2) for small molecules. Relevance criteria, common mistakes.
toxicologyspecies selectionICH S6ICH S9
ICH S2 Genotoxicity Testing: What Your Battery Actually Needs
Two battery options, five Ames strains, specific concentration caps. ICH S2(R1) genotoxicity requirements explained with the details that matter for your IND.
genotoxicityICH S2preclinicalAmes test
5 Most Common IND Deficiencies and How to Avoid Them
The 5 deficiencies that cause the most IND clinical holds and amendment cycles — with specific ICH/FDA citations, real examples, and prevention strategies for each.
INDFDAclinical holddeficiencies
How to Check Preclinical Studies Against ICH Guidelines
Step-by-step preclinical gap analysis: map studies to ICH M3(R2), verify GLP, check species, cross-reference safety pharmacology and genotoxicity batteries. With specific requirements and common mistakes.
preclinicalICHcompliancegap analysis
GLP Compliance Checklist for Preclinical Studies
Practical GLP checklist based on 21 CFR Part 58 — personnel, facilities, equipment, protocols, SOPs, QA, and reporting. What FDA inspectors actually check during GLP audits.
GLPpreclinicalFDA21 CFR Part 58
FDA IND Submission Checklist 2026: What You Actually Need
Phase 1 IND checklist for small molecule drugs — all requirements by CTD module. Forms, IND-enabling studies, CMC, clinical protocol. Free downloadable PDF. Based on 21 CFR 312.23 and ICH M3(R2).
INDFDApreclinicalchecklist
Preclinical vs Nonclinical Studies: What's the Difference
Preclinical and nonclinical mean different things in FDA regulatory context. How FDA, ICH, and industry use these terms, why it matters for IND submissions, and what goes in CTD Module 4.
preclinicalnonclinicalFDAICH
ICH Q1 Revision: Everything That's Changing in Stability Testing
ICH Q1A-F consolidated into one guideline in 2026. What changes for your stability program, what to update now, and a 7-step transition checklist for CMC teams.
ICH Q1stability testingCMCFDA
Regfo vs. Regulatory Consultants: When to Use Which
Regulatory consultants charge $300-500/hr for compliance reviews. Regfo runs the same check for $399/mo in 30 seconds. When each makes sense, when to use both.
comparisonregulatory consultantcompliancecost